Ziglam Hisham M, Baldwin David R, Daniels Ian, Andrew Jenny M, Finch Roger G
Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK.
J Antimicrob Chemother. 2002 Dec;50(6):1011-5. doi: 10.1093/jac/dkf214.
The concentrations of rifampicin in epithelial lining fluid (ELF), human alveolar macrophages (AM), bronchial mucosal biopsies and serum were measured after a single oral dose of 600 mg rifampicin from 15 patients undergoing fibre-optic bronchoscopy. The samples of ELF, AM, the bronchial mucosal biopsies and serum were obtained approximately 2-5 h after dosing. The mean concentrations (mean +/- standard error) were 5.25 mg/L (+/-0.67) in ELF, 7.93 mg/kg (+/-1.61) in bronchial biopsies, 15.48 mg/L (+/-1.41) in serum and 251.8 mg/L (+/-65.92) in alveolar macrophages. These site concentrations exceeded the MIC90 for common respiratory pathogens including Mycobacterium tuberculosis and support the observed clinical efficacy of rifampicin in the treatment of a wide range of respiratory tract infections.
对15例接受纤维支气管镜检查的患者单次口服600mg利福平后,测定其上皮衬液(ELF)、人肺泡巨噬细胞(AM)、支气管黏膜活检组织及血清中的利福平浓度。给药后约2 - 5小时采集ELF、AM、支气管黏膜活检组织及血清样本。平均浓度(平均值±标准误)在ELF中为5.25mg/L(±0.67),在支气管活检组织中为7.93mg/kg(±1.61),在血清中为15.48mg/L(±1.41),在肺泡巨噬细胞中为251.8mg/L(±65.92)。这些部位的浓度超过了包括结核分枝杆菌在内的常见呼吸道病原体的MIC90,并支持利福平在治疗多种呼吸道感染中观察到的临床疗效。